Bruker Daltonics Launches Novel APEX-QE 7 Tesla Q-q-FTMS with Unique Integrated Top Pro Top-Down Proteomics Capability.

Business Editors/Health/Medical Writers

Pittcon 2004

CHICAGO--(BUSINESS WIRE)--March 8, 2004

Top Pro(TM) Combines Selective Protein Enrichment with ECD and

BioTools(TM) Software for Most Sensitive Top-Down Protein

Sequencing and PTM Discovery

At the 2004 Pittsburgh Conference in Chicago, Bruker Daltonics Inc., an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), today announced its novel APEX(R)-QE 7 Tesla hybrid Q-q-FTMS proteomics platform for "bottom-up" and "shot-gun" proteomics. The APEX-QE is fully integrated with the novel Top Pro(TM) technology for the most sensitive top-down proteomics capabilities in FTMS.

The new APEX-QE 7T is an exceptionally easy-to-use Q-q-FTMS system for ultra-high performance proteomics mass spectrometry. Its FTMS/MS sensitivity, resolution and mass accuracy greatly surpasses alternative hybrid ion trap-FTMS combinations that mostly just operate as an ion trap in MS/MS mode without fully using the benefits of ultra-high resolution and superb mass accuracy in FTMS/MS. The APEX-QE delivers ultra-high resolution data for all measurements for consistency across large sample sets and automated overnight runs.

The APEX-QE now operates under our integrated Compass(TM) software environment for easy operation in multi-instrument laboratories, and with the most comprehensive bioinformatics analysis software suite in the industry. Running this powerful Q-q-FTMS system is now as easy as running a Bruker Daltonics ion trap for LC-ESI-MS(n) proteomics experiments. At 7 Tesla, it has an affordable list price of $750,000, which makes it accessible for many proteomics laboratories.

In addition, the APEX-QE combines the robust CID capabilities of the Q-q-front end with the unique and powerful new Top Pro(TM) technology for top-down proteomics. Top Pro(TM) integrates the uniquely sensitive selective ion enrichment capabilities of our Q-q-front-end with powerful electron capture dissociation (ECD), and our BioTools(TM) software for top-down de novo protein sequencing and the discovery of post-translational modifications (PTM).

The APEX-QE system can be an integral module of our Proteineer(TM) solution for high-success expression proteomics, including Proteineer solutions for 2D-gel based or (multi-)LC proteomics methods. APEX-QE analysis results can be managed via our ProteinScape(TM) proteomics workflow and warehousing software.

Paul Speir, Ph.D., Asst. Vice President for FTMS at Bruker Daltonics, explained: "The new APEX-QE represents an easy-to-use high-end FTMS system with superior FTMS/MS capabilities. Moreover, we have integrated all the necessary tools for probing intact protein structures as well as for the analysis of PTMs, making it extremely attractive for biological researchers. Ease-of-use is aided by Compass, our new universal software approach with an intuitive interface to the instrument and data processing, plus seamless, yet powerful data interpretation modules designed specifically for protein structure analysis and de novo sequencing."

"The most unique feature of the APEX-QE is the integrated high-sensitivity Top Pro technology. Top Pro leverages our unique ability for high duty cycle gas-phase enrichment of target proteins with high-intensity ECD as a standard feature to generate extensive structural data for low abundant proteins and post-translationally modified peptides. Finally, Top Pro also includes powerful data analysis software for the identification of PTM sites and the interrogation of unknown protein sequences. We believe that Top Pro takes top-down proteomics in FTMS to a completely new sensitivity level that will make the APEX-QE a broadly applicable proteomics tool."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.

NOTE TO EDITORS: In the product name Top Pro noted in this news release, there is a down arrow between Top and Pro. This symbol may not appear properly in some systems.